STAMFORD, Conn., June 14, 2016 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that Joshua H. Bilenker, M.D., chief executive officer, will present a corporate overview at the JMP Securities Life Sciences Conference in New York City on Wednesday, June 22, 2016 at 2:30PM ET.
A live webcast of the presentation will be available at http://ir.loxooncology.com/.
About Loxo Oncology
Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible.
Contacts for Loxo Oncology, Inc.
Jacob S. Van Naarden
Chief Business Officer
The Trout Group, LLC
Pure Communications, Inc.
Source:Loxo Oncology, Inc.